Novo Nordisk invests DKK 15.9bn to expand API production in Denmark

James Spargo | June 13, 2023 | News story | Manufacturing and Production APIs, Chronic Diseases, Novo Nordisk, chronic diseases 

Danish healthcare company Novo Nordisk has announced that it will invest another DKK 15.9bn into expanding an existing Active Pharmaceutical Ingredient (API) production facility in Hillerød, Denmark. Construction has already begun, with production expected to start by early 2029.

The new 65,000m2 facility, which will create 340 new jobs, will be designed as a multi-product facility with maximum flexibility to accommodate new processes and display a state-of-the-art working environment and technology. It will allow the company to meet future market demands and develop clinical late-stage phase products.

The news comes as Novo Nordisk continues to struggle to meet manufacturing goals for its obesity drug, Wegovy. Global demand for the drug as risen considerably, with the UK Government recently announcing a plan to introduce it to the NHS.

Henrik Wulff, executive vice president of Product Supply, Quality & IT at Novo Nordisk, stated: “This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide. The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases.”

James Spargo

Related Content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent …

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Novo Nordisk acquires Embark Biotech and its lead metabolic programme

Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset …

Latest content